Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 5;20(8):47.
doi: 10.1007/s11934-019-0912-6.

First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature

Daniele Amparore  1 , Sabrina De Cillis  1 , Gabriele Volpi  1 , Enrico Checcucci  1 , Matteo Manfredi  1 , Ivano Morra  1 , Michele Di Dio  1 , Cristian Fiori  1 , Francesco Porpiglia  2 ; ESUT Group
Affiliations

First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature

Daniele Amparore et al. Curr Urol Rep. .

Abstract

Introduction: In the last decade, there has been a growing interest in minimally invasive treatment for benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS). In this field, one of the options currently available is the temporary implantable nitinol device (iTIND) (Medi-Tate®; Medi-Tate Ltd., Or Akiva, Israel).

Purpose of the work: To review the recent data available in the literature regarding the role of the first-generation (TIND) and second-generation (iTIND) devices for the management of BPH with LUTS, especially focusing on follow-up of functional outcomes.

Evidence acquisition: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were screened for clinical trials on this topic.

Evidence synthesis: Literature evidences regarding implantation of TIND and iTIND for PBH with LUTS are limited. There are only three studies available, one with a medium-term follow-up. The results of these studies suggested that both the TIND and iTIND implantations are safe, effective, and well-tolerated procedures, allowing spare ejaculation in sexually active patients.

Conclusions: Current evidences emphasize that the temporary implantable nitinol devices are promising alternatives to the standard minimally invasive surgical options for BPH-related LUTS. Further studies are needed to confirm the effectiveness over a long-term follow-up.

Keywords: BPH; LUTS; Minimally invasive techniques; Nitinol; Urethral implantable device; iTIND.

PubMed Disclaimer

References

    1. Urology. 2000 Dec 20;56(6):899-905 - PubMed
    1. Eur Urol. 2003 Nov;44(5):539-45 - PubMed
    1. Eur Urol. 2010 Sep;58(3):356-8; discussion 358-9 - PubMed
    1. Eur Urol. 2010 Sep;58(3):384-97 - PubMed
    1. BJU Int. 2011 Apr;107(7):1030-43 - PubMed

Publication types

LinkOut - more resources